KR20130118507A - Skin external composition for anti-aging comprising 21-o-angeloyltheasapogenol e3 from green tea seed - Google Patents

Abstract

PURPOSE: An external use skin composition containing green tea seed-derived 21-O-angeloyltheasapogenol E3 for anti-aging is provided to improve anti-wrinkling and skin elasticity. CONSTITUTION: An external use skin composition contains 0.000001-5 wt% of 21-O-angeloyltheasapogenol E3 of chemical formula 1 as an active ingredient. The composition is used for anti-aging. 21-O-angeloyltheasapogenol E3 is derived from green tea seeds.

Description

Skin external composition for anti-aging comprising 21-O-angeloyltheasapogenol E3 from green tea seed containing 211-O-angeloyl deasapogenol E3 component derived from green tea seeds

The present invention relates to an anti-aging external composition for skin containing 21-O-angeloyl deasapogenol E3 component derived from green tea seed as an active ingredient, and more specifically, an acid, a base, an enzyme, or a microorganism producing the enzyme. The present invention relates to an anti-aging skin external composition for anti-aging, which has excellent wrinkle improvement and skin elasticity improvement effect by containing 21-O-angeloyl de asafogenol E3 component derived from green tea seed obtained from the seed seed extract through the decomposition reaction.

Skin aging can be roughly divided into two types depending on the factors. One of them, intrinsic aging, is that the structure and physiological functions of the skin are constantly declining while aging, and the other, extrinsic aging, is caused by accumulated external stresses such as sunlight . In particular, ultraviolet (UV) light is one of the well-known causes of aging, and the skin exposed to ultraviolet light for a long time causes the stratum corneum to become thicker, and collagen and elastin, which are the main components of the skin, are denatured and lose elasticity of the skin.

On the other hand, the elasticity of the skin is responsible for the extracelluar matrix (ECM) component of the dermal tissue, ECM is composed of two components largely. One is elastic fiber, which accounts for about 2-4% of the total ECM, and the other is collagen, which accounts for about 70-80% of the total ECM. Elastic fibers have the form of microfibrils embedded in an amorphous matrix called elastin. Elastin is found in the elastic fibers of desmosine and isodesmosine derived from lysine. It is a protein composed of unique amino acids. These desmosins and isodesmesynes form cross-links in long peptide chains, which makes elastin behave like a rubber.

In addition, elastic fibers composed of elastin are present along with collagen fibers called collagen, and it is possible to maintain skin elasticity in the state where elastin and collagen are sufficiently present.

The lowering of the skin elasticity is caused by degradation or destruction of collagen and elastin caused by aging or ultraviolet rays. In particular, due to the expression of matrix metallo protease, such as collagenase and elastase, collagen and elastin produced normally in the skin are degraded to reduce skin elasticity.

Various substances have been developed and used for the purpose of suppressing the reduction of collagen and elastin, which causes the decrease in elasticity, among which retinoids such as retinol and retinoic acid exhibit elasticity improving effects (Dermatology therapy, 1998, 16, 357-364), protein fractions obtained from Leguminosae Seeds also exhibit an elasticity-boosting effect (US Pat. No. 5,322,839), and compositions comprising malt extract inhibit collagenase. (Japanese Patent No. 5,105,693).

However, these retinoids have the drawback that irritation occurs even if only a small amount is applied to the skin. Most of the raw materials derived from natural products have been used in the form of simple extracts. The reality is that it is difficult to continuously maintain and control the activity of the extract.

Accordingly, the present inventors have studied to find a substance that exhibits an anti-aging effect and also shows an excellent skin elasticity enhancing effect. As a result, 21-O obtained from the green tea seed extract through a decomposition reaction using an acid, a base, an enzyme, or a microorganism producing the enzyme -The present invention was completed by confirming that angeloyl deasapogenol E3 component has excellent skin wrinkle improvement and skin elasticity improving effect.

Accordingly, an object of the present invention is to provide an anti-aging skin external composition comprising 21-O-angeloyl deasapogenol E3 component obtained from green tea seed extract.

In order to solve the above object, the present invention provides a composition for external application to the skin containing 21-O-angeloyl deasapogenol E3 as an active ingredient.

21-O-angeloyl deasapogenol E3 derived from green tea seed used in the present invention promotes collagen biosynthesis, thereby inhibiting the expression of elastase and collagenase, effectively improving skin wrinkles and improving skin elasticity. It can provide an excellent anti-aging effect.

The present invention provides an external preparation composition for skin containing 21-O-angeloyl deasafogenol E3 (21-O-angeloyltheasaponenol E3) represented by the following formula (1) as an active ingredient.

Said 21-O-angeloyl deasapogenol E3 is preferably derived from green tea seed.

21-O-angeloyl de asapogenol E3 used in the present invention is a first step of obtaining a crude saponin extract from a plant using water or an organic solvent; And a second step of hydrolyzing the extract using an acid, a base, an enzyme, or a microorganism producing the enzyme to separate 21-O-angeloyl deaspazogenol E3.

First Step: Obtaining the Saponin Crude Extract

A crude saponin extract is obtained from plants, especially green tea seeds. At this time, water or an organic solvent may be used as the extraction solvent, and at least one organic solvent selected from the group consisting of ethanol, methanol, butanol, ether, ethyl acetate and chloroform or a mixture thereof and water, preferably 50 % Ethanol can be used.

In order to obtain a crude saponin extract from the plant using water or an organic solvent, about 1 to 6 times, preferably about 3 times, water or an organic solvent is added to the plant, and extracted by stirring 1 to 5 times at room temperature to degrease. Let's do it. About 1 to 8 times, preferably about 4 times, water or an organic solvent is added to the degreased plant, and the mixture is extracted at reflux 1 to 5 times and then deposited at 10 to 20 ° C. for 1 to 3 days. Then, the residue and the filtrate are separated by filtration and centrifugation, and the extract obtained by concentrating the separated filtrate under reduced pressure is suspended in water, and then the dye is removed using ether or the like. The aqueous layer was extracted 1-5 times with an organic solvent, and the obtained organic solvent layer was concentrated under reduced pressure to obtain an organic solvent extract, which was then dissolved in a small amount of methanol, ethanol, propanol, butanol, and the like. Subsequently, a large amount of ethyl acetate, acetonitrile and the like can be added to dry the resulting precipitate to obtain the saponin crude extract of the present invention.

Second Step: 21-O- Angeloyl de Asapogenol E3 Separation of

The 21-O-angeloyl deaspazolol E3 may be separated by hydrolysis of the crude saponin extract obtained in the first step, and hydrolysis may be performed using an acid, a base, an enzyme, or a microorganism producing the enzyme. have.

The acid includes at least one acid selected from the group consisting of hydrochloric acid, sulfuric acid and nitric acid, or a mixed solvent of these acids with at least one alcohol selected from the group consisting of ethanol, methanol and butanol, preferably 50% ethanol Solvents may be used.

When hydrolysis is carried out using an acid, after adding 0.1-2N, preferably 1N acid, or a mixed solvent of acid and alcohol to the saponin crude extract in an amount of 1-10%, 50-100 ° C, preferably Is heated to reflux for 0.5 to 8 hours, preferably 1 hour in an 80 ℃ water bath.

The base is at least one base selected from the group consisting of sodium hydroxide and potassium hydroxide, or mixed solvent of these bases with at least one alcohol selected from the group consisting of ethanol, methanol and butanol, preferably 50% butanol Solvents may be used.

In the case of hydrolysis using a base, the crude saponin extract is dissolved in water or a mixed solvent of water and ethanol, and then a base of 0.1 to 2N, preferably 1N concentration, or a mixed solvent of base and alcohol to 1 to 10% After addition in amounts, the mixture is heated to reflux for 0.5 to 24 hours, preferably 12 hours in a 50 to 100 ° C., preferably 100 ° C. water bath.

The enzyme is characterized by producing a 21-O-angeloyl de asafogenol E3 by removing the sugar portion of the green tea saponin as an enzyme that breaks down the sugar bond. This enzyme can be used commercially available or can be prepared and used as needed, in particular from the microorganisms producing the enzyme.

In addition, the enzyme is more preferably glucosidase, arabinosidase, rhamnosidase, xylosidase, cellulase, hesperidinase (hesperidinase), naringinase, glucuronidase, glucuronidase, pectinase, galactosidase, and amyloglucosidase The above can be used.

In addition, the microorganisms producing the enzyme include Aspergillus genus, Bacillus genus, Penicillium genus, Rhizopus genus, Rhizomucor genus, Talarom One or more selected from the group consisting of genus taromyces, bifidobacterium, genus mortierella, cryptococcus and microbacterium.

When hydrolysis is performed using an enzyme, the crude saponin extract is dissolved in an acid buffer solution of 5 to 20 times, preferably about 10 times, and then the enzyme is added in an amount of 0.001 to 10%. While stirring this for about 40 to 55 hours, preferably about 48 hours in a water bath of about 25 ~ 37 ℃, by confirming the scavenging rate of the substrate by thin layer chromatography, if the substrate is completely lost, 5 to 5 in hot water (80 ~ 100 ℃) The reaction is terminated by heating for 15 minutes.

When hydrolysis is performed using microorganisms, the saponin crude extract is dissolved in 5 to 10 times, preferably about 10 times, ionized water, and then sterilized at 121 ° C for 30 minutes and cooled to 30 ° C. Then, inoculated with 5 to 10% by weight of the microorganisms incubated in advance, incubated for 2 to 5 days, preferably 5 days at 20 ~ 30 ℃, and then confirmed the scavenging rate of the substrate by thin layer chromatography When the substrate is completely lost, the precipitate obtained by centrifugation of the culture solution at 5,000 to 10,000 rpm is washed three times with distilled water, followed by centrifugation to obtain a precipitate.

After hydrolysis using an acid, a base, an enzyme, or a microorganism producing the enzyme as described above, the reaction solution is concentrated under reduced pressure to remove the solvent, and alcohol is added to the residue and stirred 1 to 5 times. Then, the precipitated salts were removed through filtration, and the filtrate was concentrated under reduced pressure to give a crude product, and the crude product obtained was separated by silica gel column chromatography (chloroform: methanol = 8: 1 to 4: 1). 21-O-angeloyl deasapogenol E3 can be obtained.

The composition of the present invention contains 21-O-angeloyl deaspazolol E3 which can be prepared by the above method in an amount of 0.000001 to 5% by weight based on the total weight of the composition. If the content is less than 0.000001% by weight, wrinkle improvement and skin elasticity effect by the above-mentioned ingredients cannot be obtained, and even if the content exceeds 5% by weight, the increase in effect is not large compared to the increase in content.

The composition of the present invention can be used as an anti-aging composition, promotes collagen biosynthesis, inhibits the expression of elastase and collagenase, and the synergistic action of these two activities results in better skin elasticity improvement and skin wrinkles. It can provide an improvement effect.

The composition of the present invention may be formulated containing a cosmetically or dermatologically acceptable medium or base. These are all formulations suitable for topical application, for example emulsions, suspensions, microemulsions, microcapsules, microgranules or ionic (liposomes) and non- It may be provided in the form of an ionic vesicle dispersant or in the form of a cream, skin, lotion, powder, ointment, spray or cone stick. It can also be used in the form of a foam or in the form of an aerosol composition further containing a compressed propellant. These compositions may be prepared according to conventional methods in the art.

In addition, the composition of the present invention is a fatty substance, organic solvent, solubilizer, thickening agent, gelling agent, softener, antioxidant, suspending agent, stabilizer, foaming agent, fragrance, surfactant, water, ionic or nonionic type Cosmetics such as emulsifiers, fillers, metal ion sequestrants, chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic actives, lipid vesicles or any other ingredient commonly used in cosmetics Or an adjuvant commonly used in the field of dermatology. Such adjuvants are introduced in amounts commonly used in the cosmetics or dermatological fields.

In addition, the composition of the present invention may contain a skin absorption promoting substance in order to increase the skin aging improvement effect.

Hereinafter, the present invention will be described in more detail by way of Examples and Test Examples, but the present invention is not limited thereto.

[Example 1] Preparation of green tea seed extract

6 kg of hexane was added to 2 kg of green tea seeds, and extracted by stirring three times at room temperature. Then, 4 l of 50% ethanol was added to 1 kg of degreased green tea seeds, and refluxed three times, followed by immersion at 15 ° C. for 1 day. Thereafter, the residue and the filtrate were separated through filter cloth filtration and centrifugation, and the extract obtained by concentrating the separated filtrate under reduced pressure was suspended in water, extracted five times with 1 L of ether to remove the pigment, and the aqueous layer was 1-butanol. Extracted three times with 500 ml. The whole 1-butanol layer obtained therefrom was concentrated under reduced pressure to obtain 1-butanol extract, which was dissolved in a small amount of methanol, and then added to a large amount of ethyl acetate, followed by drying the resulting precipitate, thereby extracting green tea seed extract (crude saponin). 300 g were obtained.

Example 2 Preparation of 21-O-angeloyl deasapogenol E3 by Acid Hydrolysis Method

20 g (v / w) of 1N HCl-50% methanol solution (v / v) was added to 10 g of the green tea seed extract obtained in Example 1, and the mixture was heated to reflux for 8 hours in an 80 ° C. water bath. Sugars bound to saponin were hydrolyzed. The reaction solution was concentrated under reduced pressure to remove the solvent, ethanol (200 mL) was added to the residue, followed by stirring three times, and the precipitated salts were removed by filtration. The filtrate was concentrated under reduced pressure to give a crude product, which was then separated by silica gel column chromatography (chloroform: methanol = 7: 1 to 3: 1) to give 21-O-angeloyl deasapogenol E3 0.55. g was obtained.

Example 3 Preparation of 21-O-angeloyl deasapogenol E3 by Base Hydrolysis Method

10 g of the green tea seed extract obtained in Example 1 was dissolved in dry pyridine (500 ml), and sodium methoxide (powder, 10 g) was added thereto to reflux for 8 hours in an oil bath to give green tea seed saponin. Bound sugars were hydrolyzed. The reaction solution was concentrated under reduced pressure to remove the solvent, ethanol (200 mL) was added to the residue, followed by stirring three times, and the precipitated salts were removed by filtration. The filtrate was concentrated under reduced pressure to give a crude product, which was then separated by silica gel column chromatography (chloroform: methanol = 8: 1 to 4: 1) to give 21-O-angeloyl deaspazolol E3 0.35. g was obtained.

Example 4 Preparation of 21-O-angeloyl deaspazogenol E3 by enzymatic digestion

10 g of the green tea seed extract obtained in Example 1 was dissolved in 100 ml of 0.1 M acetic acid buffer solution (pH 4.5), and 2.5 g of enzyme (0.5 g of hesperidinase, 0.5 g of naringinase, 0.5 cellulase) was added thereto. g, β-glucuronidase 0.2g, β-galactosidase 0.5g, amyloglucosidase 0.3g; manufactured by Sigma) was added to the thin layer chromatography while stirring for 48 hours in a 37 ° C water bath. It was confirmed periodically by, and when green tea saponin disappeared, it heated in hot water (80-100 degreeC) for 10 minutes, and reaction was complete | finished. The reaction solution was concentrated under reduced pressure to remove the solvent, ethanol (200 mL) was added to the residue, followed by stirring three times, and then the precipitate was removed by filtration. The filtrate was concentrated under reduced pressure to give a crude product. The crude product was separated by silica gel column chromatography (chloroform: methanol = 8: 1-4: 1) to obtain 21-O-angeloyl deaspazolol E3 1.02. g was obtained.

Example 5 Preparation of 21-O-angeloyl deaspazogenol E3 using microorganisms

10 g of the green tea seed extract obtained in Example 1 was dissolved in 100 ml of ionized water, sterilized at 121 ° C. for 30 minutes, cooled to 30 ° C., and then pre-cultured Aspergillus niger KCCM 11885 was prepared. 5 to 10% of the inoculation was incubated for 5 days at 30 ℃ after confirming the substrate disappearance by thin layer chromatography to confirm that the substrate completely disappeared, the precipitate was recovered by centrifugation of the culture solution at 5,000 to 10,000rpm distilled water After washing three times with centrifugation to obtain a precipitate. Ethanol (200 mL) was added to the precipitate, followed by stirring three times, and then the precipitate was removed by filtration. The filtrate was concentrated under reduced pressure to give a crude product, which was then separated by silica gel column chromatography (chloroform: methanol = 8: 1 to 4: 1) to give 21-O-angeloyl deasapogenol E3 0.72. g was obtained.

Test Example 1 Measurement of Collagen Biosynthesis Promoting Effect

The collagen biosynthesis promoting effect of 21-O-angeloyl deasapogenol E3 obtained in Examples 2 to 5 was measured in comparison with tocopherol and EGCG.

First, human fibroblasts (PromoCell, Germany) were seeded (10 ⁵ per hole) in 24 wells (seeding) and cultured until 90% growth. This was incubated in serum-free DMEM medium for 24 hours, and then treated with 10 ^-4 molarity of 21-O-angeloyl deaspazolol E3, tocopherol and EGCG of Examples 2 to 5 dissolved in serum-free medium for 24 hours, respectively. Were incubated in a CO ² incubator. These supernatants were removed and procollagen increased or decreased using procollagen type I ELISA kit (procollagen type (I)). The results are shown in Table 1 below, where the synthetic ability is compared to the non-treated group as 100.

Test substance Synthetic Performance (%) Example 2 121 Example 3 120 Example 4 121 Example 5 121 Untreated group 100 Tocopherol 113 EGCG 120

As shown in Table 1, it can be seen that 21-O-angeloyl deaspazolol E3 obtained in Examples 2 to 5 effectively increases collagen biosynthesis.

Test Example 2 Measurement of Collagenase Expression Inhibition Efficacy

The collagenase expression inhibitory effect (production inhibition) of 21-O-angeloyl deasapogenol E3 obtained in Examples 2 to 5 was measured as compared to tocopherol and EGCG to the degree of collagenase expression as follows.

First, human fibroblasts were placed in a 96-well microtiter plate containing Dulbecco's Modified Eagle's Media (DMEM) medium containing 2.5% fetal bovine serum to 5,000 cells / well. Incubate until 90% growth. After incubation for 24 hours in serum-free DMEM medium, 21-O-angeloyl deaspazogenol E3, tocopherol and EGCG (positive control) of Examples 2 to 5 dissolved in serum-free DMEM medium as a test substance 10 After treatment for 24 hours at ^-4 molarity, the cell culture was collected.

Thereafter, the collagenase production was measured using a commercially available collagenase measuring instrument (Amersham Pharma Co., Ltd.).

First, the cell culture solution collected on a 96-well plate uniformly coated with primary collagenase antibody was added and the antigen-antibody reaction was performed in a thermostatic chamber for 3 hours. After 3 hours, the second collagen antibody bound to the chromophore was placed in a 96-well plate and reacted for another 15 minutes. After 15 minutes, the coloring stimulant was added, causing color development at room temperature for 15 minutes, and 1M sulfuric acid was added again to stop the reaction (color development). The color of the reaction solution was yellow and the degree of yellow color was different according to the progress of the reaction.

The absorbance of the yellowish 96-well plate was measured at 405 nm using an absorbance meter, and the expression level of collagenase was calculated by Equation 1 below. At this time, the reaction absorbance of the collected cell culture solution of the group not treated with the test substance was taken as the absorbance of the control group. The degree of collagenase expression is shown in Table 2 below, which is prepared by comparing the level of collagenase expression of the untreated group to 100.

A: absorbance of the test substance treatment cell group

B: absorbance of control group

Test substance Collagenase
Expression degree (%) Untreated group 100 Tocopherol (positive control) 75 EGCG (positive control) 60 Example 2 59 Example 3 59 Example 4 60 Example 5 60

As shown in Table 2, when treated with 21-O-angeloyl deasapogenol E3 obtained in Examples 2 to 5, the degree of collagenase expression was lower than that of tocopherol or EGCG, which is known to inhibit collagenase expression. From this, it can be seen that 21-O-angeloyl deaspazolol E3 effectively inhibits collagenase expression.

Test Example 3 Elastase Expression Inhibition Effect Measurement

Elastase expression inhibitory efficacy (production inhibition) of 21-O-angeloyl deasapogenol E3 obtained in Examples 2 to 5 was measured as compared to tocopherol and EGCG to the extent of the expression of elastinase.

First, the test was performed to bring human fibroblasts to 5,000 cells / well in a 96-well microtiter plate containing Dulbecco's Modified Eagle's Media (DMEM) medium containing 2.5% fetal bovine serum. Incubated until incubation of about 90%. Then, incubated for 24 hours in serum-free medium, and 10 ^-4 mol of 21-O-angeloyl deaspazolol E3, tocopherol and EGCG (positive control) of Examples 2 to 5 dissolved in serum-free medium with test substance. After treatment for 24 hours at the concentration, the cell culture was collected.

Thereafter, the amount of elastase production was measured using the commercially available elastase measuring instrument (Amersham Pharmacia, USA).

First, the cell culture medium collected in a 96-well plate uniformly coated with the primary elastase antibody was subjected to an antigen-antibody reaction in a thermostat for 3 hours. After 3 hours, the secondary elastin antibody bound to the chromophore was placed in a 96-well plate and reacted again for 15 minutes. After 15 minutes, the coloring stimulant was added, causing color development at room temperature for 15 minutes, and 1M sulfuric acid was added again to stop the reaction (color development). The color of the reaction solution was yellow and the degree of yellow color was different according to the progress of the reaction.

The absorbance of the yellowish 96-well plate was measured at 405 nm using an absorbance meter, and the expression level of elastase was calculated by Equation 2 below. At this time, the reaction absorbance of the collected cell culture solution of the group not treated with the test substance was taken as the absorbance of the control group. Elastase expression degree is shown in Table 3 below, which is compared to the degree of expression of elastase in the untreated group as 100.

A: absorbance of the test substance treatment cell group

B: absorbance of control group

matter Elastase expression level (%) Untreated group 100 Tocopherol (positive control) 88 EGCG (positive control) 68 Example 2 64 Example 3 64 Example 4 65 Example 5 64

As shown in Table 3, when the 21-O-angeloyl deasafogenol E3 obtained in Examples 2 to 5 was treated, the degree of elastase expression was lower than that of tocopherol or EGCG, which is known to inhibit the expression of elastase. From this, it can be seen that 21-O-angeloyl deaspazolol E3 effectively inhibits the expression of elastase.

[Test Example 4] Confirmation of skin elasticity improving effect

In order to confirm the skin elasticity-improving effect of 21-O-angeloyl deasapogenol E3 obtained in Examples 2 to 5, the lotion of Formulation Example 1 and Comparative Example 1 was prepared as a cosmetic composition using the ingredients and contents of Table 4 below.

ingredient content Formulation Example 1 Comparative Example 1 Cetearylglucoside 1.5 1.5 Cetyl octanoate 3.0 3.0 Methylparaben 0.15 0.15 Disodium ethylenediaminetetraacetate 0.02 0.02 21-O-angeloyl deasapogenol E3 of Example 4 10 - Purified water To 100 To 100

In order to compare the skin elasticity improving effect on the lotion prepared in Formulation Example 1 and Comparative Example 1, the skin elasticity improvement degree was measured for 20 women in their 30s to 40s. The experimental method is as follows.

First, each group was given a lotion prepared in Formulation Example 1 and Comparative Example 1 was to apply a certain amount to the eyes around once a week for 12 weeks. At this time, the lotion of Formulation Example 1 was applied to the left side of the eyes of the subject, and the lotion of Comparative Example 1 was applied to the right side. Skin elasticity of each group was measured using a cutometer (SEM474, Courage + Khazaka electronic GmbH. Germany), which can measure skin elasticity before and after application of the lotion, and 12 weeks after application. Obtained. The experimental results are shown in Table 5.

division Skin elasticity improvement (%) Comparative Example 1 13 Formulation Example 1 45

As shown in Table 5, it was confirmed that the improvement of skin elasticity of the cosmetic composition of Formulation Example 1 containing 21-O-angeloyl de asafogenol E3 is three times higher than in Comparative Example 1. Therefore, it can be confirmed that the cosmetic composition containing 21-O-angeloyl de asaphogenol E3 of the present invention is very effective for improving skin elasticity.

Claims (11)

A skin external preparation composition containing 21-O-angeloyl deasapogenol E3 represented by the following Chemical Formula 1 as an active ingredient.
[Chemical Formula 1]

The external preparation composition for skin according to claim 1, wherein the composition is for anti-aging. The composition for external application for skin according to claim 1, wherein the 21-O-angeloyl deasapogenol E3 is contained in an amount of 0.000001 to 5% by weight based on the total weight of the composition. The skin external composition according to claim 1, wherein the 21-O-angeloyl deasapogenol E3 is derived from green tea seed. The external preparation composition for skin according to claim 4, wherein the 21-O-angeloyl deasapogenol E3 is obtained by decomposing the green tea seed extract using an acid, a base, an enzyme, or a microorganism producing the enzyme. 6. The external preparation composition for skin according to claim 5, wherein the acid is at least one acid selected from the group consisting of hydrochloric acid, sulfuric acid and nitric acid, or a mixed solvent of these acids with at least one alcohol selected from the group consisting of ethanol, methanol and butanol. The skin external composition according to claim 5, wherein the base is at least one base selected from the group consisting of sodium hydroxide and potassium hydroxide, or a mixed solvent of these bases with at least one alcohol selected from the group consisting of ethanol, methanol and butanol. . The method of claim 5, wherein the enzyme is a glucosidase, arabinosidase, rhamnosidase, xylosidase, cellulase, hesperidinase ( at least one selected from the group consisting of hesperidinase, naringinase, glucuronidase, glucuronidase, pectinase, galactosidase and amyloglucosidase Skin external preparation composition. According to claim 5, wherein the microorganism is genus Aspergillus, Bacillus, Bacillus, Penicillium genus, Rhizopus genus, Rhizomucor genus, Talaomyces (Talaromyces), bifidobacterium (bifidobacterium) genus, mortierella (mortierella) genus (cryptococcus) genus and microbacterium (microbacterium) at least one selected from the group consisting of skin topical composition. The external preparation composition for skin according to any one of claims 1 to 9, wherein the composition is for improving skin wrinkles. The external preparation composition for skin according to any one of claims 1 to 9, wherein the composition is for improving skin elasticity.